Stryker concluded 2025 with an outstanding fourth quarter, achieving $7.2 billion in net sales, an 11.4% increase, and adjusted EPS of $4.47, up 11.5%. The company also expanded its adjusted operating margin by 100 basis points to 30.2%, driven by healthy procedural volumes and strong demand for capital products.

Stryker delivered a strong third quarter in 2025, with consolidated net sales reaching $6.1 billion, an increase of 10.3%. The company achieved double-digit adjusted earnings per diluted share growth of 11.1% to $3.19, driven by strong execution and sustained demand across its broad portfolio.

Stryker delivered robust financial results in Q2 2025, with consolidated net sales reaching $6.0 billion, an 11.1% increase, and adjusted diluted EPS growing by 11.4% to $3.13. The company saw strong organic net sales growth of 10.2%, with significant contributions from both MedSurg and Neurotechnology, and Orthopaedics.

Stryker delivered solid Q1 2025 results, driven by continued demand for MedSurg and Orthopaedics, with revenue reaching $5.9B and adjusted EPS up 13.6% year-over-year.

Stryker reported a 10.7% increase in net sales to $6.4 billion, with organic net sales up 10.2%. Adjusted EPS increased by 15.9% to $4.01, while reported EPS decreased 52.7% to $1.41 due to non-cash charges for goodwill and other impairments. The company anticipates organic net sales growth of 8.0% to 9.0% for 2025 and adjusted net earnings per diluted share to be in the range of $13.45 to $13.70.

Stryker reported a strong Q3 2024 with net sales increasing by 11.9% to $5.5 billion and organic net sales growing by 11.5%. The company's adjusted EPS increased by 16.7% to $2.87, and they are on track to achieve their adjusted operating margin expansion goals. They now expect adjusted net earnings per diluted share to be in the range of $12.00 to $12.10.

Stryker reported a strong second quarter in 2024, with net sales increasing by 8.5% to $5.4 billion and organic net sales growing by 9.0%. The company's reported EPS increased by 10.9% to $2.14, while adjusted EPS increased by 10.6% to $2.81. Stryker is raising its full-year guidance for organic net sales growth to 9.0% to 10.0% and adjusted net earnings per diluted share to $11.90 to $12.10.

Stryker's Q1 2024 results showed a 9.7% increase in reported net sales to $5.2 billion and a 10.0% increase in organic net sales. The company's reported EPS increased by 33.1% to $2.05, and adjusted EPS increased by 16.8% to $2.50. Management is confident in the company's ability to grow sales and drive strong adjusted earnings growth in 2024.

Stryker reported an 11.8% increase in net sales to $5.8 billion and a 102.7% increase in EPS to $2.98 for Q4 2023. Organic net sales grew by 11.4%. The company surpassed $20 billion in sales for the full year and expects continued growth in 2024.

Stryker's Q3 2023 results showed a 9.6% increase in reported net sales, reaching $4.9 billion. Organic net sales grew by 9.2%. The adjusted EPS increased by 16.0% to $2.46.

Stryker reported a strong second quarter in 2023, with net sales increasing by 11.2% to $5.0 billion and organic net sales increasing by 11.9%. The company is back on its margin expansion pathway and its supercycle of innovation is progressing well. Adjusted EPS increased 12.9% to $2.54.

Stryker's Q1 2023 results showed strong performance with an 11.8% increase in reported net sales to $4.8 billion and a significant 83.3% increase in reported EPS to $1.54. Organic net sales grew by 13.6%, driven by increased unit volume and higher prices. The company has raised its full-year 2023 outlook for organic net sales growth and adjusted net earnings per diluted share.

Stryker reported strong fourth-quarter results with a 10.7% increase in net sales, reaching $5.2 billion, and a 13.2% increase in organic net sales. Adjusted EPS increased by 10.7% to $3.00. The company anticipates continued sales momentum in 2023.

Stryker reported a 7.7% increase in net sales to $4.5 billion for the third quarter of 2022. Organic net sales grew by 9.9%. Reported EPS increased 87.7% to $2.14, while adjusted EPS decreased 3.6% to $2.12. The company is taking actions to address persistent issues like foreign currency and inflation.

Stryker reported a 4.6% increase in net sales to $4.5 billion, with organic net sales increasing by 6.1%. Reported EPS increased by 11.0% to $1.72, while adjusted EPS was $2.25. The company is confident in its full year outlook for revenue.

Stryker reported an 8.1% increase in net sales to $4.3 billion and a 9.2% increase in organic net sales. The company's reported EPS increased by 6.3% to $0.84, while adjusted EPS increased by 2.1% to $1.97.

Stryker reported a 10.3% increase in net sales compared to 2020, reaching $4.7 billion. The reported EPS increased by 16.1% to $1.73, while adjusted EPS decreased by 3.6% to $2.71.

Stryker reported a solid third quarter in 2021 with net sales increasing by 11.3% compared to 2020 and 16.0% compared to 2019, reaching $4.2 billion. The company saw growth in MedSurg and NeuroTech businesses, although U.S. implant related businesses were impacted by deferred procedures due to a resurgence of COVID-19. Reported EPS decreased by 30.1% to $1.14, while adjusted EPS increased by 2.8% to $2.20.

Stryker reported a significant increase in net sales and earnings for the second quarter of 2021. Net sales increased by 55.4% compared to 2020 and 17.6% compared to 2019, reaching $4.3 billion. The company's strong performance was attributed to the moderation of the pandemic and the successful integration of Wright Medical.

Stryker reported a 10.2% increase in net sales and a 4.9% increase in adjusted EPS for the first quarter of 2021. The company is optimistic about continued momentum and the Wright Medical integration.

Stryker reported a 3.2% increase in net sales to $4.3 billion for Q4 2020. Despite challenges from the COVID-19 pandemic, the company's adjusted EPS increased by 12.9% to $2.81. The Wright Medical integration is off to a strong start, and innovation continues across the company.

Stryker reported a 4.2% increase in net sales to $3.7 billion for the third quarter of 2020. Organic net sales increased by 3.3%. Reported EPS increased 32.5% to $1.63, and adjusted EPS increased 12.0% to $2.14.

Stryker's Q2 2020 results were significantly impacted by the COVID-19 pandemic, leading to a 24.3% decrease in reported net sales to $2.8 billion. The company reported a net loss of $83 million, or $0.22 per diluted share, but adjusted EPS was $0.64. Due to the uncertain scope and duration of the pandemic, Stryker is not providing third quarter or full-year organic sales growth or earnings guidance for 2020.

Stryker reported a 2.0% increase in net sales, reaching $3.6 billion. Despite the negative impact of the COVID-19 pandemic, the company's reported EPS increased by 19.3% to $1.30, and net earnings increased by 19.7% to $493 million.

Stryker reported an 8.8% increase in net sales, reaching $4.1 billion, and an 8.0% rise in organic net sales for Q4 2019. The adjusted EPS increased by 14.2% to $2.49, surpassing the high end of the guidance range. The company's performance was driven by growth across all business segments and geographies, contributing to an excellent finish to the year.